Paul Farrant

Paul Farrant

Auto-generated profile, based on publicly available information

Paul Farrant

University Hospitals Sussex NHS Foundation Trust , Sussex

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
MHMatthew Harries
Matthew Harries
AAAnna Ascott
Anna Ascott
LALeila Asfour
Leila Asfour
PFPaul Farrant
Paul Farrant
GHGordon Hale
Gordon Hale
BUBritish Association of Dermatologists’ Clinical Standards Unit
British Association of Dermatologists’ Clinical Standards Unit
Lay Summary: Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Total loss of scalp hair is called alopecia totalis (AT). Complete loss of scalp, facial and body hair is called alopecia universalis (AU). The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of 11 dermatologists, 1 psychologist, 2 people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 19 October 2023. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 49 recommendations for management of people with AA. They also made 7 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, the group prepared an updated patient information leaflet. The leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).

27 October 2023 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
SVSergio Vano-Galvan
Sergio Vano-Galvan
UBUlrike Blume-Peytavi
Ulrike Blume-Peytavi
PFPaul Farrant
Paul Farrant
PRPascal Reygagne
Pascal Reygagne
EJErin Johansson
Erin Johansson
Bianca Maria PiracciniBianca Maria Piraccini
Bianca Maria Piraccini
Introduction Alopecia areata (AA) can negatively affect quality of life (QoL) and is associated with increased prevalence of anxiety and depression (vs people without AA). This study compared physician-assessed and patient self-rated severity of AA in a European sample and described the patient-reported burden of AA stratified by physician-assessed severity. Methods Real-world data were collected from the Adelphi Real World AA Disease Specific Programme™, a retrospective point-in-time cross-sectional survey of dermatologists and their adult patients with AA in five European countries (France, Germany, Italy, Spain, UK). Physicians provided clinical data and an AA severity assessment, according to their own definition of ‘mild’, ‘moderate’ and ‘severe’. Patients were invited to provide their perception of AA severity and completed patient-reported outcome (PRO) questionnaires, including Skindex-16 for AA (Skindex-16 AA), EuroQol-5-dimension questionnaire 5-level (EQ-5D-5L), Hospital Anxiety and Depression Scale and the Work Productivity and Activity Impairment Questionnaire. Results Data for 2083 patients were collected by 239 physicians; 561 of these patients completed PRO questionnaires. In 78.5% of cases with available data (N = 549), there was alignment between patient and physician-rated AA severity (severity was rated higher by physicians in 15.7% of cases, by patients in 5.8% of cases). Data from all PRO instruments showed an increase in patient-reported burden and work and activity impairment with increasing physician-rated AA severity. For the Skindex-16 AA, the Emotions scale had the worst scores; anxiety/depression was the EQ-5D-5L dimension with the highest percentages of patients reporting any perceived problem. Conclusions These data highlight the significant impact that AA can have beyond hair loss, especially for patients with severe AA. There was substantial physician–patient alignment on severity assessment. Higher physician-rated AA severity was associated with higher levels of patient-reported disease burden, including anxiety and depression, and work and activity impairment. These data may help inform appropriate treatment strategies.

1 October 2016 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
AMA.E. Macbeth
A.E. Macbeth
JTJ. Tomlinson
J. Tomlinson
AMAndrew Guy Messenger
Andrew Guy Messenger
KMK. Moore-Millar
K. Moore-Millar
CMC. Michaelides
C. Michaelides
MHMatthew Harries
Matthew Harries
Background Alopecia areata (AA) is a common hair loss disorder that results in patchy to complete hair loss. Many uncertainties exist around the most effective treatments for this condition. Objectives To identify uncertainties in AA management and treatment that are important to both service users (people with hair loss, carers and relatives) and healthcare professionals. Methods An AA priority setting partnership was established between patients, their carers and relatives, and healthcare professionals to identify the most important uncertainties in AA. The methodology of the James Lind Alliance was followed to ensure a balanced, inclusive and transparent process. Results In total, 2747 treatment uncertainties were submitted by 912 participants, of which 1012 uncertainties relating to AA (and variants) were analysed. Questions were combined into ‘indicative uncertainties’ following a structured format. A series of ranking exercises further reduced this list to a top 25 that were taken to a final prioritization workshop where the top 10 priorities were agreed. Conclusions We present the top 10 research priorities for AA to guide researchers and funding bodies to support studies important to both patients and clinicians.

14 November 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
MHMatthew Harries
Matthew Harries
AAAlia Ahmed
Alia Ahmed
AAAnna Ascott
Anna Ascott
KBKashif Bhatti
Kashif Bhatti
JEJoseph Earley
Joseph Earley
ACAlina M Constantin
Alina M Constantin
Lay Summary: Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Alopecia totalis is the name for total loss of scalp hair. Alopecia universalis is complete loss of scalp, facial and body hair. This is the second version of the guideline. The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of eight consultant dermatologists, one dermatology specialist registrar, one general practitioner, one psychologist, two people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 11 July 2025. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 56 recommendations for management of people with AA. They also made 9 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, a patient information leaflet is also available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).

23 July 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
NMNekma Meah
Nekma Meah
JLJane Li
Jane Li
DWDmitri Wall
Dmitri Wall
KYKatherine York
Katherine York
BBBevin Bhoyrul
Bevin Bhoyrul
RSRodney Sinclair
Rodney Sinclair
Background: As the incidence of frontal fibrosing alopecia (FFA) continues to rise, there is a need for an optimal treatment algorithm for FFA. Objectives: To produce an international consensus statement on the treatment modalities and prognostic indicators of FFA. Methods: Sixty‐nine hair experts from six continents were invited to participate in a three‐round Delphi process. The final stage was held as a virtual meeting facilitated via Zoom. The consensus threshold was set at ≥66%. Results: Of 365 questions, expert consensus was achieved in 204 (56%) questions following completion of the three rounds. Three additional questions were included at the final meeting. The category with the strongest consensus agreement was disease monitoring (9; 100%). Questions pertaining to physical therapies achieved the least category consensus (15; 40%), followed by systemic therapy (45; 43%). Limitations: The study lacked sufficient representation from Africa and South America. Conclusions: SOFFIA highlights areas of agreement and disagreement among experts. Robust research is warranted to provide evidence‐based treatment recommendations.

17 August 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
ATAnita Takwale
Anita Takwale
EAEmily Arthur
Emily Arthur
JPJulian Pearce
Julian Pearce
PFPaul Farrant
Paul Farrant
SHSusan Holmes
Susan Holmes
MHMatthew Harries
Matthew Harries
Background: Global and trichoscopic photography are fundamental in the clinical assessment of hair loss. At present, standardized protocols for hair loss photography are lacking. Objectives: To create novel, pragmatic and flexible standardized photography protocols for hair loss that are practical to use for clinicians and medical photographers alike. Methods: Published disease severity scales for a variety of hair loss conditions were utilized to create standardized photography protocols. These protocols were reviewed and refined by a national clinical working group of consultant dermatologists specializing in hair loss. Results: Three main presentation-based protocols are provided, defined by the type of hair loss a patient may present with, including pattern loss, frontal fibrosing alopecia/traction alopecia, alopecia areata and other patchy hair loss disorders. Additional supplementary protocols facilitate further specific views for a variety of individualized clinical scenarios, based on user discretion. Conclusions: We present novel, pragmatic, standardized photography protocols for hair loss disorders. These can be used by clinicians even where formal medical photography units are unavailable. Standardization allows for the creation of high-quality, informative images for objective assessment and monitoring of hair loss in clinical practice and in research settings.